Verisyse versus Veriflex Phakic Intraocular Lenses: Refractive Outcomes and Endothelial Cell Density 5 Years after Surgery

Table 6

Endothelial changes over the course of the study.

	Preoperative	1 year	3 years	5 years
	Central ECD (cells/mm^2) (mean ± SD (% of cumulative ECD loss))
Verisyse	2681 ± 275 (N/A)	2599 ± 242 (3.05)	2534 ± 238 (5.48)	2482 ± 242 (7.42)
Veriflex	2656 ± 270 (N/A)	2575 ± 253 (3.04)	2512 ± 251 (5.42)	2460 ± 282 (7.64)
	0.692	0.670	0.678	0.709
	Coefficient of variation of cell area (%)
Verisyse	30.8 ± 5.5	29.0 ± 5.7	29.4 ± 4.3	29.1 ± 5.8	0.083
Veriflex	30.0 ± 5.2	30.6 ± 5.2	30.5 ± 5.4	31.2 ± 6.0	0.233
	0.515	0.185	0.699	0.117
	Hexagonal cells (%)
Verisyse	65.4 ± 7.5	66.1 ± 7.3	64.8 ± 6.9	66.0 ± 8.2	0.114
Veriflex	62.7 ± 7.7	64.7 ± 8.4	63.9 ± 8.2	64.4 ± 8.8	0.142
	0.130	0.422	0.601	0.396

Repeated measures ANOVA, value for all visits. Independent samples t-test. ^†Post hoc analysis: statistically significant difference was observed from the preoperative visit to the 1-year visit (), from the 1-year visit to 3-year visit (), and from 3-year visit to 5-year visit (). ^††Post hoc analysis: statistically significant difference was observed from the preoperative visit to the 1-year visit (), from the 1-year visit to 3-year visit (), and from 3-year visit to 5-year visit ().